

Rodney J Hicks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2757753/publications.pdf>

Version: 2024-02-01

502
papers

27,857
citations

6233

80
h-index

8599

146
g-index

509
all docs

509
docs citations

509
times ranked

24202
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 571-578.	0.8	1,275
2	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	0.8	1,269
3	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet</i> , The, 2020, 395, 1208-1216.	6.3	1,108
4	[¹⁷⁷ Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 825-833.	5.1	823
5	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , The, 2011, 12, 933-980.	5.1	571
6	Prognostic Significance of [¹⁸ F]-Misonidazole Positron Emission Tomographyâ€“Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02. <i>Journal of Clinical Oncology</i> , 2006, 24, 2098-2104.	0.8	532
7	Somatostatin Receptor Imaging with ⁶⁸ Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation. <i>Radiographics</i> , 2015, 35, 500-516.	1.4	435
8	Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1285-1292.	0.8	414
9	Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Nonâ€“Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. <i>Clinical Cancer Research</i> , 2012, 18, 2391-2401.	3.2	387
10	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1211-1223.	13.9	343
11	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. <i>Neuroendocrinology</i> , 2017, 105, 212-244.	1.2	325
12	⁹⁰ Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide. <i>Journal of Clinical Oncology</i> , 2010, 28, 1652-1659.	0.8	299
13	MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome. <i>Brain</i> , 2004, 127, 2276-2285.	3.7	290
14	Dosimetry of ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 517-523.	2.8	285
15	High rate of detection of unsuspected distant metastases by PET in apparent Stage III nonâ€“small-cell lung cancer: implications for radical radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 287-293.	0.4	284
16	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015, 75, 5228-5234.	0.4	270
17	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , 2015, 125, 3679-3687.	0.6	270
18	EANM procedure guidelines for radionuclide therapy with ¹⁷⁷ Lu-labelled PSMA-ligands (¹⁷⁷ Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	3.3	265

#	ARTICLE	IF	CITATIONS
19	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. <i>Radiographics</i> , 2018, 38, 200-217.	1.4	262
20	Response of <i>BRAF</i> -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. <i>Cancer Discovery</i> , 2014, 4, 423-433.	7.7	242
21	Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. <i>Head and Neck</i> , 2005, 27, 175-181.	0.9	233
22	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues. <i>Neuroendocrinology</i> , 2017, 105, 295-309.	1.2	229
23	F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma. <i>Cancer</i> , 2001, 92, 886-895.	2.0	221
24	High management impact of Ga ⁶⁸ DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 40-47.	0.9	217
25	Clinical Impact of ¹⁸ F Fluorodeoxyglucose Positron Emission Tomography in Patients With Non-Small-Cell Lung Cancer: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 111-118.	0.8	215
26	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137.	3.3	208
27	Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 1527-1533.	0.8	204
28	FDG PET/CT for assessing tumour response to immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 238-250.	3.3	194
29	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 857-865.	2.8	191
30	Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 535-542.	0.8	183
31	An activating <i>Pik3ca</i> mutation coupled with <i>Pten</i> loss is sufficient to initiate ovarian tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 553-557.	3.9	174
32	Marked, Homogeneous, and Early [¹⁸ F]Fluorodeoxyglucose-Positron Emission Tomography Responses to Vemurafenib in <i>BRAF</i> -Mutant Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1628-1634.	0.8	172
33	A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2006, 78, 254-261.	0.3	169
34	Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 412-418.	0.4	165
35	Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. <i>Lung Cancer</i> , 2005, 49, 95-108.	0.9	165
36	Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. <i>American Journal of Medicine</i> , 2002, 112, 262-268.	0.6	159

#	ARTICLE	IF	CITATIONS
37	Role of ¹⁸ F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2009, 50, 31S-42S.	2.8	137
38	Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1384-1391.	3.3	135
39	Is there still a role for SPECT-CT in oncology in the PET-CT era?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 712-720.	12.5	135
40	⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. <i>Cancer Imaging</i> , 2016, 16, 22.	1.2	135
41	Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. <i>Head and Neck</i> , 2007, 29, 986-995.	0.9	134
42	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for ¹⁷⁷ Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2019, 2, 670-676.	2.6	134
43	Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?. <i>Epilepsia</i> , 2013, 54, 1240-1250.	2.6	129
44	Changes in ¹⁸ F-Fluorodeoxyglucose and ¹⁸ F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib. <i>Clinical Cancer Research</i> , 2011, 17, 3304-3315.	3.2	126
45	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3278-3287.	1.8	125
46	The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. <i>Gynecologic Oncology</i> , 2009, 112, 462-468.	0.6	124
47	The impact of PET/CT in the management of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 271-276.	0.6	123
48	Impact of [¹⁸ F] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 213-219.	0.4	120
49	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1733-1742.	0.5	120
50	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	1.3	120
51	The tumour sink effect on the biodistribution of ⁶⁸ Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 50-56.	3.3	119
52	Investigations with FDG-PET Scanning in Prostate Cancer Show Limited Value for Clinical Practice. <i>Acta Oncologica</i> , 2002, 41, 425-429.	0.8	115
53	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 67-77.	3.3	112
54	Quantitative ¹⁷⁷ Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. <i>Cancer Imaging</i> , 2011, 11, 56-66.	1.2	111

#	ARTICLE	IF	CITATIONS
55	The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. <i>Journal of Nuclear Medicine</i> , 2002, 43, 492-9.	2.8	111
56	Does Positron Emission Tomography Change Management in Primary Rectal Cancer? A Prospective Assessment. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 451-458.	0.7	107
57	The extent of resection of FDG-PET hypometabolism relates to outcome of temporal lobectomy. <i>Brain</i> , 2007, 130, 548-560.	3.7	107
58	Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. <i>Journal of Nuclear Medicine</i> , 2006, 47, 14-22.	2.8	107
59	The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. <i>British Journal of Cancer</i> , 2009, 100, 693-700.	2.9	103
60	¹⁸ F-FDG PET/CT Has a High Impact on Patient Management and Provides Powerful Prognostic Stratification in the Primary Staging of Esophageal Cancer: A Prospective Study with Mature Survival Data. <i>Journal of Nuclear Medicine</i> , 2012, 53, 864-871.	2.8	102
61	Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 87-96.	0.3	102
62	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2322-2327.	3.3	101
63	Improving Diagnosis of Tumor-Induced Osteomalacia With Gallium-68 DOTATATE PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 687-694.	1.8	100
64	⁶⁴ Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 777-785.	2.8	98
65	Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 262-277.	3.3	97
66	Imaging Cellular Proliferation During Chemo-Radiotherapy: A Pilot Study of Serial 18F-FLT Positron Emission Tomography/Computed Tomography Imaging for Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1098-1104.	0.4	96
67	A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. <i>BJU International</i> , 2018, 122, 783-793.	1.3	96
68	Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 176-185.	3.3	91
69	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.	3.3	91
70	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	5.1	90
71	Multicenter Phase II Clinical Study of Iodine-131-Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4418-4425.	0.8	89
72	Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. <i>Medical Journal of Australia</i> , 2010, 193, 46-52.	0.8	89

#	ARTICLE	IF	CITATIONS
73	Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 3026-3031.	0.8	88
74	Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2007, 10, 203-11.	0.9	88
75	⁶⁸ Ga PET/CT Ventilation-Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1513-1519.	2.8	87
76	Impact of Positron Emission Tomography on the Management of Patients With Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 164-171.	0.6	86
77	Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE. <i>Epilepsia</i> , 2012, 53, 1233-1244.	2.6	85
78	PET imaging of tumours with a ⁶⁴ Cu labeled macrobicyclic cage amine ligand tethered to Tyr ³ -octreotate. <i>Dalton Transactions</i> , 2014, 43, 1386-1396.	1.6	85
79	Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 215.	1.3	85
80	18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1223-1229.	2.8	84
81	High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 157-162.	0.3	83
82	FAPI PET/CT: Will It End the Hegemony of ¹⁸ F-FDG in Oncology?. <i>Journal of Nuclear Medicine</i> , 2021, 62, 296-302.	2.8	82
83	Depression in Temporal Lobe Epilepsy Surgery Patients: An FDG-PET Study. <i>Epilepsia</i> , 2006, 47, 2125-2130.	2.6	81
84	Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 2072-2082.	3.3	81
85	How We Read Oncologic FDG PET/CT. <i>Cancer Imaging</i> , 2016, 16, 35.	1.2	81
86	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021, 17, 435-444.	4.3	80
87	Validating and improving CT ventilation imaging by correlating with ventilation 4D-PET/CT using ⁶⁸ Ga-labeled nanoparticles. <i>Medical Physics</i> , 2013, 41, 011910.	1.6	79
88	Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1831-1844.	3.3	79
89	Regulation of rDNA transcription in response to growth factors, nutrients and energy. <i>Gene</i> , 2015, 556, 27-34.	1.0	79
90	Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. <i>Journal of the American College of Cardiology</i> , 1991, 18, 101-111.	1.2	78

#	ARTICLE	IF	CITATIONS
91	Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 351-361.	0.4	78
92	Frequent Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography on the Staging and Management of Patients with Indolent Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 43-49.	2.1	78
93	Initial Staging of Lymphoma With Positron Emission Tomography and Computed Tomography. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 165-175.	2.5	78
94	Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non-“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, e71-e72.	0.5	78
95	The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. <i>Head and Neck</i> , 2003, 25, 138-145.	0.9	77
96	A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies. <i>Chemical Communications</i> , 2016, 52, 11889-11892.	2.2	77
97	Differential ¹⁸ F-FDG and ¹⁸ F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-“Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1069-1074.	2.8	76
98	An In vivo Tumor Model Exploiting Metabolic Response as a Biomarker for Targeted Drug Development. <i>Cancer Research</i> , 2005, 65, 9633-9636.	0.4	75
99	Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. <i>Cancer Imaging</i> , 2010, 10, 83-91.	1.2	74
100	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. <i>Lancet Haematology</i> , 2015, 2, e445-e455.	2.2	74
101	Patterns of Failure and Prognostic Factor Analyses in Locally Advanced Cervical Cancer Patients Staged by Positron Emission Tomography and Treated With Curative Intent. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 912-918.	1.2	73
102	Effect of PET/CT on Management of Patients with Non-“Small Cell Lung Cancer: Results of a Prospective Study with 5-Year Survival Data. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1007-1015.	2.8	73
103	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <i>European Journal of Cancer</i> , 2013, 49, 3936-3944.	1.3	72
104	Overview of early response assessment in lymphoma with FDG-PET. <i>Cancer Imaging</i> , 2007, 7, 10-18.	1.2	71
105	<i>In Vivo</i> Activity of Combined PI3K/mTOR and MEK Inhibition in a <i>KrasG12D</i> ; <i>Pten</i> Deletion Mouse Model of Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1440-1449.	1.9	70
106	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 504-508.	0.6	70
107	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. <i>Thyroid</i> , 2019, 29, 1634-1645.	2.4	69
108	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. <i>Neurotherapeutics</i> , 2019, 16, 192-202.	2.1	69

#	ARTICLE	IF	CITATIONS
109	Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 43-49.	0.8	68
110	Radiation Dosimetry in ¹⁷⁷ Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1030-1036.	2.8	68
111	Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2004, 26, 1008-1017.	0.9	67
112	High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose- ϵ positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 5030-5037.	2.0	67
113	The Cost-Effective Use of 18F-FDG PET in the Presurgical Evaluation of Medically Refractory Focal Epilepsy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 931-937.	2.8	66
114	Progressive Metabolic and Structural Cerebral Perturbations After Traumatic Brain Injury: An In Vivo Imaging Study in the Rat. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1788-1795.	2.8	66
115	An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. <i>Medical Physics</i> , 2013, 40, 112503.	1.6	66
116	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. <i>Journal of Nuclear Medicine</i> , 2020, 61, 626-629.	2.8	65
117	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of ⁶⁸ Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 625-631.	2.8	62
118	Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 759-769.	3.3	61
119	Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography Before and After Definitive Radiation Therapy in Patients With Apparently Solitary Plasmacytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 740-746.	0.4	61
120	¹⁸ F-Flumazenil: A β -Aminobutyric Acid A ϵ -Specific PET Radiotracer for the Localization of Drug-Resistant Temporal Lobe Epilepsy. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1270-1277.	2.8	61
121	The genomic landscape of pheochromocytoma. <i>Journal of Pathology</i> , 2015, 236, 78-89.	2.1	61
122	How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?. <i>Cancer</i> , 2007, 109, 117-124.	2.0	60
123	¹⁷⁷ Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity ¹¹¹ In-octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1869-1875.	3.3	60
124	¹⁸ F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. <i>Skeletal Radiology</i> , 2011, 40, 1007-1015.	1.2	60
125	FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 770-778.	3.3	59
126	Reproducibility of ϵ Intelligent ϵ Contouring of Gross Tumor Volume in Non ϵ Small-Cell Lung Cancer on PET/CT Images Using a Standardized Visual Method. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1151-1157.	0.4	59

#	ARTICLE	IF	CITATIONS
127	High-Contrast PET of Melanoma Using ¹⁸ F-MELO50, a Selective Probe for Melanin with Predominantly Renal Clearance. <i>Journal of Nuclear Medicine</i> , 2010, 51, 441-447.	2.8	59
128	Changing paradigms with molecular imaging of neuroendocrine tumors. <i>Discovery Medicine</i> , 2012, 14, 71-81.	0.5	59
129	PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 747-748.	2.8	58
130	Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. <i>Cancer</i> , 2011, 117, 3981-3988.	2.0	57
131	The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: Results of a prospective study with mature survival data. <i>Radiotherapy and Oncology</i> , 2013, 106, 292-298.	0.3	57
132	New Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with ⁶⁸ Ga ³⁺ . <i>Bioconjugate Chemistry</i> , 2016, 27, 309-318.	1.8	57
133	ORIGINAL ARTICLE: Pilot comparison of ¹⁸ F-fluorocholine and ¹⁸ F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2010, 54, 325-332.	0.9	56
134	Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1798-1807.	3.2	56
135	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. <i>International Journal of Cancer</i> , 2018, 142, 2139-2152.	2.3	56
136	Imaging of hypoxia with ¹⁸ F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 475-481.	0.9	55
137	Intra-individual comparison of ⁶⁸ Ga-PSMA-11 and ¹⁸ F-DCFPyL normal-organ biodistribution. <i>Cancer Imaging</i> , 2019, 19, 23.	1.2	55
138	Enhancing the anti-tumour activity of ¹⁷⁷ Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. <i>Scientific Reports</i> , 2020, 10, 10196.	1.6	54
139	Association Between Pulmonary Uptake of Fluorodeoxyglucose Detected by Positron Emission Tomography Scanning After Radiation Therapy for Non-Small-Cell Lung Cancer and Radiation Pneumonitis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1365-1371.	0.4	53
140	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With ¹⁸ F-FDG PET/CT in Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 971-976.	0.7	53
141	A Phase IIa Randomized Control Trial of ⁷⁵ Se (Sodium Selenate) in Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 223-232.	1.2	53
142	Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. <i>Haematologica</i> , 2017, 102, 356-363.	1.7	53
143	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	1.3	53
144	Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1086-1092.	5.1	52

#	ARTICLE	IF	CITATIONS
145	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	51
146	Pretreatment Transcriptional Profiling for Predicting Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 3039-3047.	3.2	50
147	Discovery of [¹⁸ F] <i>N</i> -(2-(Diethylamino)ethyl)-6-fluoronicotinamide: A Melanoma Positron Emission Tomography Imaging Radiotracer with High Tumor to Body Contrast Ratio and Rapid Renal Clearance. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5299-5302.	2.9	49
148	Gallium-68 Complex of a Macrobicyclic Cage Amine Chelator Tethered to Two Integrin-Targeting Peptides for Diagnostic Tumor Imaging. <i>Bioconjugate Chemistry</i> , 2011, 22, 2093-2103.	1.8	49
149	The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2013, 106, 288-291.	0.3	49
150	Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1417-1422.	1.9	48
151	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , 2008, 19, 547-552.	0.7	48
152	The role of PET in monitoring therapy. <i>Cancer Imaging</i> , 2005, 5, 51-57.	1.2	47
153	Where Do We Draw the Line? Contouring Tumors on Positron Emission Tomography/Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 2-4.	0.4	47
154	¹⁸ F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1559-1564.	2.8	47
155	PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 71-81.	2.5	47
156	The Use of Positron Emission Tomography (PET) in the Staging/Evaluation, Treatment, and Follow-Up of Patients With Lung Cancer: A Critical Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1298-1306.	0.4	46
157	Peptide Receptor Radionuclide Therapy with ⁶⁷ Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1800-1805.	2.8	46
158	¹⁸ F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , 2020, 20, 36.	1.2	46
159	The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 1994, 1, 3-16.	1.4	45
160	Analysis of ¹⁷⁷ Lu-DOTA-Octreotate Therapy-Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2015, 56, 505-511.	2.8	45
161	TERT structural rearrangements in metastatic pheochromocytomas. <i>Endocrine-Related Cancer</i> , 2018, 25, 1-9.	1.6	45
162	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5873-5882.	3.2	45

#	ARTICLE	IF	CITATIONS
163	Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. <i>Cancer Imaging</i> , 2018, 18, 3.	1.2	45
164	Prediction of outcome after revascularization in patients with poor left ventricular function. <i>Annals of Thoracic Surgery</i> , 1996, 61, 1428-1434.	0.7	44
165	The Role of Positron Emission Tomography/Computed Tomography in Radiation Therapy Planning for Patients with Lung Cancer. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 308-319.	2.5	44
166	Bayesian approach to determining penetrance of pathogenic SDH variants. <i>Journal of Medical Genetics</i> , 2018, 55, 729-734.	1.5	44
167	High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 343-349.	3.3	43
168	High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 527-533.	0.7	42
169	High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 476-489.	3.3	42
170	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2776-2786.	3.3	42
171	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	3.2	42
172	PET scanning in lung cancer: Current status and future directions. <i>Journal of Surgical Oncology</i> , 2003, 21, 149-155.	1.4	41
173	PET/CT: will it change the way that we use CT in cancer imaging?. <i>Cancer Imaging</i> , 2006, 6, S52-S62.	1.2	41
174	Ventilation/Perfusion Positron Emission Tomography-Based Assessment of Radiation Injury to Lung. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 408-417.	0.4	41
175	FDG-PET-Detected Extracranial Metastasis in Patients with Non-Small Cell Lung Cancer Undergoing Staging for Surgery or Radical Radiotherapy. <i>Acta Oncologica</i> , 2003, 42, 48-54.	0.8	40
176	Peptide Receptor Radiotherapy: Current Approaches and Future Directions. <i>Current Treatment Options in Oncology</i> , 2019, 20, 77.	1.3	40
177	Rapid kit-based 68Ga-labelling and PET imaging with THP-Tyr3-octreotate: a preliminary comparison with DOTA-Tyr3-octreotate. <i>EJNMMI Research</i> , 2015, 5, 52.	1.1	39
178	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 943-950.	2.8	39
179	Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 441-452.	3.3	38
180	'MRI-negative PET-positive' temporal lobe epilepsy (TLE) and mesial TLE differ with quantitative MRI and PET: a case control study. <i>BMC Neurology</i> , 2007, 7, 16.	0.8	38

#	ARTICLE	IF	CITATIONS
181	[18F]Fluorodeoxyglucose Positron Emission Tomography Scanning for Staging, Response Assessment, and Disease Surveillance in Patients with Mantle Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 159-165.	1.4	38
182	In Vivo Tracking of Dendritic Cells in Patients With Multiple Myeloma. <i>Journal of Immunotherapy</i> , 2008, 31, 166-179.	1.2	38
183	The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification. <i>Cancer Imaging</i> , 2014, 14, 13.	1.2	38
184	Detection of Synchronous Primary Malignancies with ⁶⁸ Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1938-1942.	2.8	38
185	Clinical applications of molecular imaging in sarcoma evaluation. <i>Cancer Imaging</i> , 2005, 5, 66-72.	1.2	37
186	Improving Patient Selection for ¹⁸ F-FDG PET Scanning in the Staging of Gastric Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 523-529.	2.8	37
187	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1902-1910.	3.3	37
188	Validation of a 4D-PET Maximum Intensity Projection for Delineation of an Internal Target Volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 749-754.	0.4	36
189	Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1212-1217.	2.8	36
190	Myeloid neoplasms after chemotherapy and PRRT: myth and reality. <i>Endocrine-Related Cancer</i> , 2016, 23, C1-C7.	1.6	36
191	Molecular imaging in the investigation of hypoglycaemic syndromes and their management. <i>Endocrine-Related Cancer</i> , 2017, 24, R203-R221.	1.6	36
192	Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 347-353.	3.3	35
193	Correlation of p16 status, hypoxic imaging using [¹⁸ F]misonidazole positron emission tomography and outcome in patients with locally advanced head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 89-97.	0.9	35
194	¹⁸ F-FDG "Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. <i>Journal of Nuclear Medicine</i> , 2018, 59, 749-755.	2.8	35
195	High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 991-1001.	3.3	34
196	Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumes. <i>Radiation Oncology</i> , 2014, 9, 291.	1.2	34
197	Differential ¹⁸ F-FDG and ³ H-Deoxy- ³ H- ¹⁸ F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1261-1267.	2.8	33
198	Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 114-121.	0.8	33

#	ARTICLE	IF	CITATIONS
199	Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of α ²³ Integrin Expression with Gallium-68. <i>Bioconjugate Chemistry</i> , 2017, 28, 481-495.	1.8	33
200	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , 2021, 12, 5049.	5.8	33
201	Hypoxia in Head and Neck Cancer: Studies With Hypoxic Positron Emission Tomography Imaging and Hypoxic Cytotoxins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S61-S63.	0.4	32
202	PET for Sarcomas Other Than Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2008, 13, 22-26.	1.9	32
203	Radiation Changes Do Not Interfere With Postchemoradiation Restaging of Patients With Rectal Cancer by FDG PET/CT Before Curative Surgical Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 60-66.	0.4	32
204	Improved Detection of Regional Melanoma Metastasis Using ¹⁸ F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-Specific PET Probe, by Perilesional Administration. <i>Journal of Nuclear Medicine</i> , 2011, 52, 115-122.	2.8	32
205	Rapid blood clearance and lack of long-term renal toxicity of ¹⁷⁷ Lu-DOTATATE enables shortening of renoprotective amino acid infusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1853-1860.	3.3	32
206	⁶⁸ Ga-EDTA PET/CT Imaging and Plasma Clearance for Glomerular Filtration Rate Quantification: Comparison to Conventional ⁵¹ Cr-EDTA. <i>Journal of Nuclear Medicine</i> , 2015, 56, 405-409.	2.8	32
207	A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 14991-14994.	7.2	32
208	Functional imaging techniques for evaluation of sarcomas. <i>Cancer Imaging</i> , 2005, 5, 58-65.	1.2	31
209	Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1348-1355.	3.3	31
210	Distribution Atlas of Proliferating Bone Marrow in Non-Small Cell Lung Cancer Patients Measured by FLT-PET/CT Imaging, With Potential Applicability in Radiation Therapy Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1035-1043.	0.4	31
211	Does PET SUV Harmonization Affect PERCIST Response Classification?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1699-1706.	2.8	31
212	Impact of complementary parathyroid scintigraphy and ultrasonography on the surgical management of hyperparathyroidism. <i>Surgery</i> , 1996, 120, 845-851.	1.0	30
213	Early therapeutic response assessment by ¹⁸ F-FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. <i>Leukemia and Lymphoma</i> , 2007, 48, 596-600.	0.6	30
214	Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 947-955.	0.4	30
215	Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on ⁶⁸ Ga-DOTATATE PET/CT and ¹⁸ F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 204-216.	3.3	30
216	¹⁸ F-FDG PET as a Surrogate Biomarker in Non-Small Cell Lung Cancer Treated with Erlotinib: Newly Identified Lesions Are More Informative Than Standardized Uptake Value. <i>Journal of Nuclear Medicine</i> , 2012, 53, 530-537.	2.8	29

#	ARTICLE	IF	CITATIONS
217	Correlation of ⁶⁸ Ga Ventilation-Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1718-1723.	2.8	29
218	Gallium-68 EDTA PET/CT for Renal Imaging. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 448-461.	2.5	29
219	Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1034-1043.	1.8	29
220	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. <i>European Urology Oncology</i> , 2019, 2, 152-162.	2.6	29
221	Imaging in the diagnosis and treatment of non-small cell lung cancer. <i>Respirology</i> , 2007, 12, 165-172.	1.3	28
222	A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2013, 49, 468-474.	0.8	28
223	CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	28
224	Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose ⁶⁷ Ga SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 506-515.	3.3	27
225	Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 827-833.	1.2	27
226	The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 28-33.	0.6	27
227	Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 211-213.	3.3	27
228	Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. <i>Annals of Hematology</i> , 2005, 84, 118-121.	0.8	26
229	Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 642-650.	3.3	26
230	A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 740.	1.1	26
231	15-Year Experience of ¹⁸ F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1328-1333.	2.8	26
232	Bifunctional ⁶⁴ Cu-labelled macrobicyclic cage amine isothiocyanates for immuno-positron emission tomography. <i>Dalton Transactions</i> , 2015, 44, 4901-4909.	1.6	26
233	Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 617-625.	3.3	26
234	Radiosynthesis and Biological Evaluation of ¹⁸ F-(3-[(¹⁸ F]Fluoropropyl)homocysteine for Tumor Imaging Using Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1860-1870.	2.9	25

#	ARTICLE	IF	CITATIONS
235	Cancer imaging: Quo vadis?. <i>Cancer Imaging</i> , 2014, 14, 1.	1.2	25
236	The difference between medicine and magic is that magicians know what they are doing. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1-4.	3.3	25
237	Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups. <i>Inorganic Chemistry</i> , 2019, 58, 4540-4552.	1.9	25
238	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. <i>Annals of Neurology</i> , 2019, 85, 241-250.	2.8	25
239	PET/MRI: a different spin from under the rim. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 10-14.	3.3	24
240	Moving Beyond "Lumpology": PET/CT Imaging of Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2015, 21, 3815-3817.	3.2	24
241	What ¹⁸ F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 328-334.	2.8	24
242	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸ F-Fluoromethylcholine or ⁶⁸ Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1253-1258.	2.8	24
243	The clinical significance and management of lesion motion due to respiration during PET/CT scanning. <i>Cancer Imaging</i> , 2011, 11, 224-36.	1.2	24
244	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , 2019, 134, 756-756.	0.6	24
245	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸ F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1386-1406.	3.3	24
246	The Utility of 2-Deoxy-2-[¹⁸ F]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin. <i>Molecular Imaging and Biology</i> , 2005, 7, 236-243.	1.3	23
247	Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1889-1895.	0.6	23
248	Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by ¹⁸ F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1075-1080.	2.8	23
249	The Role of ⁶⁸ Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5091-5099.	1.8	23
250	In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 958-965.	3.3	22
251	In Vivo Measurement of Hippocampal GABAA/cBZR Density with [¹⁸ F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy. <i>PLoS ONE</i> , 2014, 9, e86722.	1.1	22
252	Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the THMYCN neuroblastoma mouse model. <i>International Journal of Cancer</i> , 2016, 139, 194-204.	2.3	22

#	ARTICLE	IF	CITATIONS
253	Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1969-1971.	2.8	22
254	¹⁸ F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors. <i>PET Clinics</i> , 2020, 15, 11-22.	1.5	22
255	Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1326-1330.	2.8	22
256	¹³⁷ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , 2021, 9, 612-623.	1.6	22
257	Efficacy and Safety of ¹⁷⁷ Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 218-225.	2.8	22
258	PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. <i>Lung Cancer</i> , 2005, 47, 49-57.	0.9	21
259	Atypical Brown Fat Distribution in Young Males Demonstrated on PET/CT. <i>Clinical Nuclear Medicine</i> , 2007, 32, 679-682.	0.7	21
260	One-step radiosynthesis of 4-nitrophenyl 2-[¹⁸ F]fluoropropionate ([¹⁸ F]NFP); improved preparation of radiolabeled peptides for PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 726-730.	0.5	21
261	Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. <i>Oncologist</i> , 2014, 19, 175-176.	1.9	21
262	¹⁸ F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1825-1832.	3.3	21
263	Accuracy and Utility of Deformable Image Registration in ⁶⁸ Ga 4D PET/CT Assessment of Pulmonary Perfusion Changes During and After Lung Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 196-204.	0.4	21
264	PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110538.	1.4	21
265	Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics. <i>BioDrugs</i> , 2003, 17, 339-354.	2.2	20
266	Absence of a Relationship between Tumor ¹⁸ F-fluorodeoxyglucose Standardized Uptake Value and Survival in Patients Treated with Definitive Radiotherapy for Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 377-382.	0.5	20
267	The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. <i>Oncologist</i> , 2017, 22, 272-285.	1.9	20
268	⁶⁸ Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. <i>Cancer Imaging</i> , 2017, 17, 31.	1.2	20
269	Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy. <i>PLoS ONE</i> , 2015, 10, e0142608.	1.1	20
270	¹⁸ F-FDG PET in candidates for radiation therapy: is it important and how do we validate its impact?. <i>Journal of Nuclear Medicine</i> , 2003, 44, 30-2.	2.8	20

#	ARTICLE	IF	CITATIONS
271	Use of carbon-11 acetate and dynamic positron emission tomography to assess regional myocardial oxygen consumption in patients with acute myocardial infarction receiving thrombolysis or coronary angioplasty. <i>American Journal of Cardiology</i> , 1993, 71, 529-535.	0.7	19
272	The motivations and methodology for high-throughput PET imaging of small animals in cancer research. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1497-1509.	3.3	19
273	Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 25-32.	3.3	19
274	Recent developments in radiolabelled peptides for PET imaging of cancer. <i>Tetrahedron Letters</i> , 2016, 57, 4119-4127.	0.7	19
275	Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery. <i>Cancer Imaging</i> , 2016, 16, 24.	1.2	19
276	Automatic delineation of functional lung volumes with 68Ga-ventilation/perfusion PET/CT. <i>EJNMMI Research</i> , 2017, 7, 82.	1.1	19
277	PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1869-1877.	3.3	19
278	Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. <i>International Journal of Cancer</i> , 2020, 146, 1316-1323.	2.3	19
279	Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model. <i>JCO Precision Oncology</i> , 2021, 5, 1001-1012.	1.5	19
280	Impact of PET on Radiation Therapy Planning in Lung Cancer. <i>Radiologic Clinics of North America</i> , 2007, 45, 627-638.	0.9	18
281	The role of PET-CT in the management of patients with advanced cancer of the head and neck. <i>Current Oncology Reports</i> , 2008, 10, 149-155.	1.8	18
282	Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?. <i>Cancer Imaging</i> , 2012, 12, 315-323.	1.2	18
283	Treatment response in the neck: p16+ versus p16 ⁺ oropharyngeal cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 364-372.	0.9	18
284	Vacuum immobilisation reduces tumour excursion and minimises intrafraction error in a cohort study of stereotactic ablative body radiotherapy for pulmonary metastases. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 244-252.	0.9	18
285	Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. <i>BJU International</i> , 2019, 124, 551-553.	1.3	18
286	High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1330-1336.	3.3	17
287	Modifying the Poor Prognosis Associated with ¹⁸ F-FDG Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT). <i>Journal of Nuclear Medicine</i> , 2015, 56, 968-969.	2.8	17
288	Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 718-727.	3.3	17

#	ARTICLE	IF	CITATIONS
289	An approach to ventricular efficiency by use of carbon 11-labeled acetate and positron emission tomography. <i>Journal of Nuclear Cardiology</i> , 1994, 1, 262-269.	1.4	16
290	Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible. <i>Medical Journal of Australia</i> , 2001, 175, 303-307.	0.8	16
291	EEG dipole source localization of interictal spikes in non-lesional TLE with and without hippocampal sclerosis. <i>Epilepsy Research</i> , 2010, 92, 183-190.	0.8	16
292	Doing More Harm than Good? Do Systematic Reviews of PET by Health Technology Assessment Agencies Provide an Appraisal of the Evidence That Is Closer to the Truth than the Primary Data Supporting Its Use?. <i>Journal of Nuclear Medicine</i> , 2011, 52, 64S-73S.	2.8	16
293	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1553-1559.	2.8	16
294	Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e200-e205.	0.9	16
295	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. <i>Cancer Discovery</i> , 2022, 12, 2058-2073.	7.7	16
296	Assessment of myocardial oxidative metabolism in aortic valve disease using positron emission tomography with C-11 acetate. <i>American Heart Journal</i> , 1992, 123, 653-664.	1.2	15
297	The role of thallium-201 and pentavalent dimercaptosuccinic acid for staging cartilaginous tumours. <i>International Seminars in Surgical Oncology</i> , 2004, 1, 10.	1.1	15
298	Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia. <i>Medical Journal of Australia</i> , 2005, 182, 172-176.	0.8	15
299	Imaging in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 165-177.	0.7	15
300	Postchemotherapy and Tumor-Selective Targeting with the La-Specific DAB4 Monoclonal Antibody Relates to Apoptotic Cell Clearance. <i>Journal of Nuclear Medicine</i> , 2014, 55, 772-779.	2.8	15
301	Incremental diagnostic utility of gastric distension FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 644-653.	3.3	15
302	Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1596-1604.	3.3	15
303	Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. <i>Investigational New Drugs</i> , 2020, 38, 844-854.	1.2	15
304	Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with ⁶⁷ Cu. <i>Journal of Nuclear Medicine</i> , 2021, 62, 829-832.	2.8	15
305	[¹⁸ F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Haematology</i> , 2022, 9, e573-e584.	2.2	15
306	PRINCE: Phase I trial of ¹⁷⁷ Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5017-5017.	0.8	15

#	ARTICLE	IF	CITATIONS
307	Assessment of right ventricular oxidative metabolism by positron emission tomography with C-11 acetate in aortic valve disease. <i>American Journal of Cardiology</i> , 1991, 67, 753-757.	0.7	14
308	Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. <i>Acta Orthopaedica</i> , 1997, 68, 25-36.	1.4	14
309	PET tracer development - a tale of mice and men. <i>Cancer Imaging</i> , 2006, 6, S102-S106.	1.2	14
310	A prospective investigation into the clinical impact of 4D-PET/CT in the characterisation of solitary pulmonary nodules. <i>Cancer Imaging</i> , 2014, 14, 24.	1.2	14
311	Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. <i>Acta Oncologica</i> , 2015, 54, 1105-1112.	0.8	14
312	Nuclear Medicine in Cancer Theranostics: Beyond the Target. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1659-1660.	2.8	14
313	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. <i>EJNMMI Physics</i> , 2017, 4, 17.	1.3	14
314	Diagnostic challenges in a patient with an occult insulinoma: ⁶⁸ Ga-DOTA-exendin4 PET/CT and ⁶⁸ Ga-DOTATATE PET/CT. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 719-722.	0.2	14
315	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13044.	1.2	14
316	Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner. <i>Medical Journal of Australia</i> , 1999, 171, 529-532.	0.8	13
317	Beyond FDG: novel PET tracers for cancer imaging. <i>Cancer Imaging</i> , 2003, 4, 22-24.	1.2	13
318	A First-in-Human Study of ⁶⁸ Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1837-1842.	2.8	13
319	Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 80-86.	3.3	13
320	Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9258-9270.	2.9	13
321	First clinical study of a pegylated diabody ¹²⁴ I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. <i>Theranostics</i> , 2020, 10, 11404-11415.	4.6	13
322	Hiatus Hernia: A Potential Cause of False-Positive Iodine-131 Scan in Thyroid Carcinoma. <i>Clinical Nuclear Medicine</i> , 1998, 23, 621-622.	0.7	13
323	PET/CT variants and pitfalls in malignant melanoma. <i>Cancer Imaging</i> , 2022, 22, 3.	1.2	13
324	Imaging immunity in patients with cancer using positron emission tomography. <i>Npj Precision Oncology</i> , 2022, 6, 24.	2.3	13

#	ARTICLE	IF	CITATIONS
325	Positron emission tomography myocardial viability studies in patients with diabetes mellitus viability. Journal of the American College of Cardiology, 1991, 17, A121.	1.2	12
326	Metabolic imaging by positron emission tomography early after myocardial infarction as a predictor of recovery of myocardial function after reperfusion. Journal of Nuclear Cardiology, 1994, 1, 124-137.	1.4	12
327	Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy*. Journal of Medical Imaging and Radiation Oncology, 2001, 45, 483-490.	0.6	12
328	Lamina-specific changes in hippocampal GABAA/cBZR and mossy fibre sprouting during and following amygdala kindling in the rat. Neurobiology of Disease, 2009, 35, 337-347.	2.1	12
329	Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour. Clinical Endocrinology, 2014, 81, 940-942.	1.2	12
330	Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on 68Ga-PSMA and 18F-FDG PET/CT: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, 1-5.	0.9	12
331	Molecular Imaging of Recurrent and Metastatic Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 280-293.	2.5	12
332	Early Outcomes of Surgery for Carcinoid Heart Disease. Heart Lung and Circulation, 2020, 29, 742-747.	0.2	12
333	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13040.	1.2	12
334	Role of Functional Imaging in Head and Neck Squamous Cell Carcinoma: Fluorodeoxyglucose Positron Emission Tomography and Beyond. Hematology/Oncology Clinics of North America, 2008, 22, 1221-1238.	0.9	11
335	The risk of exaggerated risk aversion—a life and death struggle for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1693-1694.	3.3	11
336	White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism. EJNMMI Research, 2011, 1, 2.	1.1	11
337	Enhanced White Adipose Tissue Metabolism in Iatrogenic Cushing's Syndrome With FDG PET/CT. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3041-3042.	1.8	11
338	The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. Cancer Imaging, 2020, 20, 68.	1.2	11
339	FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. Cancer Imaging, 2021, 21, 57.	1.2	11
340	Insulin-glucose clamp for standardization of metabolic conditions during F-18 fluoro-deoxyglucose pet imaging. Journal of the American College of Cardiology, 1991, 17, A381.	1.2	10
341	Discordant Response to Chemotherapy Detected by PET Scanning. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 368-370.	0.6	10
342	Sex and SUVmax: Sex-Dependent Prognostication in Early Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 1676-1685.	2.8	10

#	ARTICLE	IF	CITATIONS
343	Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. <i>EJNMMI Research</i> , 2012, 2, 31.	1.1	10
344	Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901. <i>Nuclear Medicine and Biology</i> , 2014, 41, 148-154.	0.3	10
345	A New Theranostic Paradigm for Advanced Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1493-1494.	2.8	10
346	[¹⁷⁷ Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer – Author's reply. <i>Lancet Oncology</i> , The, 2018, 19, e373.	5.1	10
347	Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 204-211.	0.4	10
348	A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4841-4856.	2.9	10
349	Differential Effects of Bisphosphonate on Paget's Disease and Metastatic Prostatic Carcinoma-Bone Scan Findings. <i>Clinical Nuclear Medicine</i> , 2001, 26, 347-348.	0.7	10
350	Role of PET-CT in the Optimization of Thoracic Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 81-84.	0.5	10
351	Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice. <i>PLoS ONE</i> , 2014, 9, e95847.	1.1	10
352	Machine learning approaches for imaging-based prognostication of the outcome of surgery for mesial temporal lobe epilepsy. <i>Epilepsia</i> , 2022, 63, 1081-1092.	2.6	10
353	Iodine-123N- methyl-4-iododexetimide: a new radioligand for single-photon emission tomographic imaging of myocardial muscarinic receptors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 339-345.	2.2	9
354	Radiosynthesis of [¹²³ I]N-methyl-4-iododexetimide and [¹²³ I]N-methyl-4-iodolevetimide: In vitro and in vivo characterisation of binding to muscarinic receptors in the rat heart. <i>Nuclear Medicine and Biology</i> , 1996, 23, 147-153.	0.3	9
355	How can we tell if PET imaging for cancer is cost effective?. <i>Lancet Oncology</i> , The, 2010, 11, 711-712.	5.1	9
356	Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1112-1115.	0.5	9
357	The Role of Positron Emission Tomography/Computed Tomography in Planning Radiotherapy in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 645-649.	1.2	9
358	Lung Cancer. <i>PET Clinics</i> , 2015, 10, 147-158.	1.5	9
359	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. <i>Journal of Pathology</i> , 2017, 242, 273-283.	2.1	9
360	How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology. <i>Cancer Imaging</i> , 2019, 19, 57.	1.2	9

#	ARTICLE	IF	CITATIONS
361	Voxelwise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. <i>BJU International</i> , 2019, 123, 1020-1030.	1.3	9
362	Applied Systems Biology embracing molecular imaging for systemic medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2721-2725.	3.3	9
363	Utility of ⁶⁸ Ga- ϵ DOTA- ϵ Xendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. <i>Internal Medicine Journal</i> , 2021, 51, 1657-1664.	0.5	9
364	The Value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in Lung Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 734-744.	2.5	9
365	Inadvertent 2-deoxy-2-[18F]fluoro-D-glucose lymphoscintigraphy: a potential pitfall characterized by hybrid PET-CT. <i>Molecular Imaging and Biology</i> , 2002, 4, 276-278.	1.3	8
366	Role of PET-CT in the Optimization of Thoracic Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 81-84.	0.5	8
367	Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate. <i>International Journal of Radiation Biology</i> , 2012, 88, 1009-1018.	1.0	8
368	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. <i>Oncotarget</i> , 2016, 7, 48887-48904.	0.8	8
369	Sulfonation of Tyrosine as a Method To Improve Biodistribution of Peptide-Based Radiotracers: Novel ¹⁸ F-Labeled Cyclic RGD Analogues. <i>Molecular Pharmaceutics</i> , 2017, 14, 1169-1180.	2.3	8
370	Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 869-870.	2.8	8
371	An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement. <i>Journal of Nuclear Medicine</i> , 2019, 60, 480-485.	2.8	8
372	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. , 2020, 8, e000700.		8
373	Carboplatin dosing in the era of IDMS-creatinine; the Cockcroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. <i>Gynecologic Oncology</i> , 2020, 157, 793-798.	0.6	8
374	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma. <i>Nature Communications</i> , 2022, 13, 1100.	5.8	8
375	Association between false negative hepatobiliary scans and initial gallbladder visualization after 30 min. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 1990, 16, 747-753.	2.2	7
376	Ga-67 SPECT: ave atque vale! Or have we bid a premature farewell to a trusted friend?. <i>Leukemia and Lymphoma</i> , 2006, 47, 2440-2442.	0.6	7
377	The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 105-119.	1.5	7
378	Restaging: Should We PERCIST Without Pattern Recognition?. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1830-1832.	2.8	7

#	ARTICLE	IF	CITATIONS
379	Are Health Economics Making Us Sick?. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1665-1667.	2.8	7
380	The Evolving Role of Molecular Imaging in Non-“Small Cell Lung Cancer Radiotherapy. <i>Seminars in Radiation Oncology</i> , 2015, 25, 133-142.	1.0	7
381	Citius, Altius, Fortius: An Olympian Dream for Theranostics. <i>Journal of Nuclear Medicine</i> , 2017, 58, 194-195.	2.8	7
382	Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. <i>EJNMMI Research</i> , 2019, 9, 15.	1.1	7
383	The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!. <i>Cancer Imaging</i> , 2019, 19, 28.	1.2	7
384	FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2471-2476.	0.6	7
385	Technical Note: Rapid multiexponential curve fitting algorithm for voxel-based targeted radionuclide dosimetry. <i>Medical Physics</i> , 2020, 47, 4332-4339.	1.6	7
386	Novel RET Fusion <i><i>RET-SEPTIN9</i></i> Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. <i>JCO Precision Oncology</i> , 2021, 5, 1160-1165.	1.5	7
387	Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG). <i>Blood</i> , 2015, 126, 815-815.	0.6	7
388	Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 228-228.	0.8	7
389	A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. <i>Haematologica</i> , 2008, 93, 789-790.	1.7	6
390	Positron Emission Tomography and Neoadjuvant Therapy of Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 111-115.	0.9	6
391	Scatter Limitation to Correct for Arm Movement in PET/CT. <i>Clinical Nuclear Medicine</i> , 2012, 37, 786-787.	0.7	6
392	Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 703-712.	3.3	6
393	The Customer Is Always Right, Even When You Are Justifiably Wrong. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1923-1924.	2.8	6
394	Synthesis and in Vivo Evaluation of [123I]Melanin-Targeted Agents. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6214-6224.	2.9	6
395	How I read cancer imaging studies: the master class series. <i>Cancer Imaging</i> , 2016, 16, 8.	1.2	6
396	Radiopharmaceuticals in paraganglioma imaging: too many members on board?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 391-393.	3.3	6

#	ARTICLE	IF	CITATIONS
397	Strand breakage by decay of DNA-bound ¹²⁴ I provides a basis for combined PET imaging and Auger endoradiotherapy. <i>International Journal of Radiation Biology</i> , 2016, 92, 686-697.	1.0	6
398	The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. <i>Annals of Surgical Oncology</i> , 2019, 26, 4673-4680.	0.7	6
399	Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. <i>Internal Medicine Journal</i> , 2019, 49, 615-621.	0.5	6
400	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1094-1095.	2.8	6
401	Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor. <i>Chemical Science</i> , 2021, 12, 9004-9016.	3.7	6
402	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. <i>Blood</i> , 2019, 134, 3999-3999.	0.6	6
403	Health technology assessment and cancer imaging: who should be setting the agenda?. <i>Cancer Imaging</i> , 2004, 4, 58-60.	1.2	5
404	The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: How do we reconcile conflicting results in the era of evidence-based medicine?. <i>Leukemia and Lymphoma</i> , 2006, 47, 2008-2010.	0.6	5
405	What is the role of ¹⁸ F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1653-1656.	0.6	5
406	A Dual Radiologic Contrast Agent Protocol for ¹⁸ F-FDG and ¹⁸ F-FLT PET/CT Imaging of Mice Bearing Abdominal Tumors. <i>Molecular Imaging and Biology</i> , 2011, 13, 518-525.	1.3	5
407	Not-So-Random Errors: Randomized Controlled Trials Are Not the Only Evidence of the Value of PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1820-1822.	2.8	5
408	Evaluation of a new visual uptake scoring scale for ¹⁸ F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. <i>Nuclear Medicine Communications</i> , 2013, 34, 521-526.	0.5	5
409	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 417-427.	1.2	5
410	Automated preparation of [¹⁸ F]fluoropropionate labeled peptides using a flexible, multi-stage synthesis platform (iPHASE Flexlab). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 61-67.	0.5	5
411	Imaging Somatostatin Positive Tumors with Tyr ³ -Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68. <i>Bioconjugate Chemistry</i> , 2021, 32, 1192-1203.	1.8	5
412	Role of PET-CT in the optimization of thoracic radiotherapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 81-4.	0.5	5
413	Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms. <i>Cancer Imaging</i> , 2022, 22, .	1.2	5
414	Breast lymphatic drainage via the pulmonary lymphatic system. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2203-2203.	3.3	4

#	ARTICLE	IF	CITATIONS
415	Not-So-Random Errors: Randomized Controlled Trials Are Not the Only Evidence of the Value of PET—Rebuttal. <i>Journal of Nuclear Medicine</i> , 2013, 54, 492-492.	2.8	4
416	Let's Get SEERious: More Accurate Staging With Consequent High Management Impact Is Not Just Stage Migration. <i>Journal of Clinical Oncology</i> , 2013, 31, 819-819.	0.8	4
417	Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 559-564.	0.5	4
418	Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma. <i>Frontiers in Surgery</i> , 2015, 2, 36.	0.6	4
419	Acute radiation oesophagitis associated with 2-deoxy-2-[18F]fluoro-D-glucose uptake on positron emission tomography/CT during chemo-radiation therapy in patients with non-small-cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 682-688.	0.9	4
420	Learning from Failure; Hypoxia Is an Evil Foe. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1043-1044.	2.8	4
421	Follow up results of a prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 76-82.	0.9	4
422	The Injustice of Being Judged by the Errors of Others: The Tragic Tale of the Battle for PET Reimbursement. <i>Journal of Nuclear Medicine</i> , 2018, 59, 418-420.	2.8	4
423	Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. <i>Internal Medicine Journal</i> , 2018, 48, 97-98.	0.5	4
424	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 656611.	1.3	4
425	Segmental Hyperperfusion in Lobar Pneumonia Visualized with Respiratory-gated Four-Dimensional Pulmonary Perfusion Positron Emission Tomography—Computed Tomography. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 104-105.	2.5	4
426	Automated preparation of clinical grade [68Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platform. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 23.	1.8	4
427	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 250-264.	0.4	4
428	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 37-39.	0.3	4
429	Simulated bone metastases: A case study of two patients with breast cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 1999, 43, 365-368.	0.6	3
430	The SUV and FLT PET: A tasty alphabet soup or a dog's breakfast?. <i>Leukemia and Lymphoma</i> , 2007, 48, 649-652.	0.6	3
431	PET for Therapeutic Response Monitoring in Oncology. <i>PET Clinics</i> , 2008, 3, 89-99.	1.5	3
432	Association between radiation pneumonitis and tumor response in patients with NSCLC treated with chemoradiation. <i>Radiation Oncology</i> , 2014, 9, 217.	1.2	3

#	ARTICLE	IF	CITATIONS
433	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. Journal of Clinical Oncology, 2015, 33, 1221-1223.	0.8	3
434	Statistically Assigned Response Criteria in Solid Tumors (STARCISt). Cancer Imaging, 2015, 15, 9.	1.2	3
435	THYROPET Study: Is It Biology or Technology That Is the Issue?. Journal of Nuclear Medicine, 2017, 58, 354.1-354.	2.8	3
436	A new model for training in hybrid imaging. Lancet Oncology, The, 2018, 19, 1152-1154.	5.1	3
437	Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. Journal of Critical Care, 2020, 60, 319-322.	1.0	3
438	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. Journal of Clinical Oncology, 2014, 32, 9006-9006.	0.8	3
439	Pitfalls and Immune-Related Adverse Events. , 2020, , 101-115.		3
440	Cardiac Blood-Pool Imaging in Oncology. Clinical Nuclear Medicine, 2001, 26, 18-26.	0.7	2
441	Using positron emission tomography to assess tumor proliferation in non-Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 183-185.	0.6	2
442	Imaging, radiation oncology and randomised trials: Time for a change?. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 97-100.	0.9	2
443	Imaging of molecular target modulation in oncology: challenges of early clinical trials. Clinical and Translational Imaging, 2014, 2, 5-12.	1.1	2
444	Short and long-term prognostic implications of a low embolic burden in oncology patients diagnosed with symptomatic pulmonary embolism. Annals of Hematology, 2016, 95, 651-652.	0.8	2
445	Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin. American Journal of Hematology, 2016, 91, 1167-1168.	2.0	2
446	â€˜Hot spotâ€™ cardiac ischemia imaging with fluorodeoxyglucose positron emission tomography. Journal of Nuclear Cardiology, 2016, 23, 1514-1517.	1.4	2
447	PET Imaging for Endocrine Malignancies: From Woe to Go. Journal of Nuclear Medicine, 2017, 58, 878-880.	2.8	2
448	Radiosynthesis and preliminary <i>in vivo</i> evaluation of ¹⁸ F-labelled glycosylated duramycin peptides for imaging of phosphatidylethanolamine during apoptosis. MedChemComm, 2019, 10, 1930-1934.	3.5	2
449	The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸ F) positron emission tomography positive intermediate grade pancreatic neuroendocrine tumors. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 150-157.	0.7	2
450	Intra-patient comparison of physiologic ⁶⁸ Ga-PSMA-11 and ¹⁸ F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay. Cancer Imaging, 2021, 21, 35.	1.2	2

#	ARTICLE	IF	CITATIONS
451	Primary Bone Tumors. , 2006, , 267-301.		2
452	First in-human study of in vivo imaging of ex vivo labeled CAR T cells with dual PET-MR.. Journal of Clinical Oncology, 2020, 38, 3557-3557.	0.8	2
453	^{18}F Fluoro Azomycin Arabinoside (^{18}F FAZA): Synthesis, Radiofluorination and Preliminary PET Imaging of Murine A431 Tumors. Current Radiopharmaceuticals, 2017, 10, 93-101.	0.3	2
454	Longitudinal changes of focal cortical glucose hypometabolism in adults with chronic drug resistant temporal lobe epilepsy. Brain Imaging and Behavior, 2021, 15, 2795-2803.	1.1	2
455	Surgery for primary hyperparathyroidism 1962-1996: Indications and outcomes. Medical Journal of Australia, 1998, 169, 118-119.	0.8	1
456	F-18 PET Soft Tissue Uptake in Seatbelt Injury. Clinical Nuclear Medicine, 2004, 29, 809-810.	0.7	1
457	Impact of PET on Radiation Therapy Planning. PET Clinics, 2006, 1, 317-328.	1.5	1
458	Time and Again, Children Resemble Their Parents. Journal of Nuclear Medicine, 2008, 49, 1577-1578.	2.8	1
459	The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project: Response to a letter from Dr. Maurie Markman. Gynecologic Oncology, 2009, 114, 536-537.	0.6	1
460	Reply to G. Keramida et al. Journal of Clinical Oncology, 2015, 33, 4121-4122.	0.8	1
461	Re: Palliative bypass for small bowel carcinoid with mesenteric mass and vascular encasement. ANZ Journal of Surgery, 2015, 85, 197-197.	0.3	1
462	Complementary role of MRI and positron emission tomography in diagnosing cerebral abscess in a patient with metastatic paraganglioma. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 525-527.	0.9	1
463	Characterizing high-grade serous papillary carcinoma of tunica vaginalis. Urology Case Reports, 2019, 26, 100949.	0.1	1
464	A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. Angewandte Chemie, 2019, 131, 15133-15136.	1.6	1
465	Molecular Imaging in the Era of Precision Medicine: Paraganglioma as a Template for Understanding Multiple Levels of Analysis. Journal of Nuclear Medicine, 2020, 61, 646-648.	2.8	1
466	Nodal metabolic tumour volume on baseline ^{18}F -FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative-intent chemoradiotherapy/radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 748-754.	0.9	1
467	Back to the Future: Nuclear Medicine Rediscovered Its Therapeutic Roots. , 2016, , 277-287.		1
468	Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.. Journal of Clinical Oncology, 2017, 35, 9563-9563.	0.8	1

#	ARTICLE	IF	CITATIONS
469	Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.. Journal of Clinical Oncology, 2018, 36, 5040-5040.	0.8	1
470	The "ProPSMA Study" clinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy.. Journal of Clinical Oncology, 2019, 37, TPS138-TPS138.	0.8	1
471	Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.. Journal of Global Oncology, 2019, 5, 6-6.	0.5	1
472	Intratumoral T cell repertoire is predictive of interim PET scan results in patients with diffuse large B cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 2021, 10, e1351.	1.7	1
473	Facts and Myths About Stage Migration: Should the Will Rogers Phenomenon Ride off into the Distance?. European Urology Oncology, 2022, , .	2.6	1
474	Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷ Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5027-5027.	0.8	1
475	Title is missing!. Clinical Nuclear Medicine, 2003, 28, 487-488.	0.7	0
476	PET Scanning in Staging and Evaluation of Response to Treatment in Lung Cancer. , 2005, , 461-471.		0
477	In Reply to Dr. Faraci and Colleagues. International Journal of Radiation Oncology Biology Physics, 2008, 72, 304.	0.4	0
478	Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier. Leukemia and Lymphoma, 2009, 50, 865-867.	0.6	0
479	PET and PET/CT in Treatment Planning. Medical Radiology, 2011, , 173-186.	0.0	0
480	Cancer Imaging reviewer acknowledgement 2015. Cancer Imaging, 2016, 16, .	1.2	0
481	Role of PET/CT in Melanoma. , 2017, , 37-51.		0
482	PET/CT in Melanoma (Additional Teaching Cases). , 2017, , 53-63.		0
483	New Challenges in Nuclear Endocrinology. Journal of Nuclear Medicine, 2018, 59, 573-574.	2.8	0
484	Does addition of a diagnostic contrast-enhanced CT to a contemporaneous PET/CT provide incremental value in patients for restaging of colorectal carcinoma?. European Journal of Hybrid Imaging, 2018, 2, .	0.6	0
485	2020 vision or myopia? A personal perspective on the future of cancer imaging and an introduction to the sequels to the "How I Read Series": Cancer Imaging, 2019, 19, 7.	1.2	0
486	Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy. Cancers, 2020, 12, 991.	1.7	0

#	ARTICLE	IF	CITATIONS
487	Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. <i>Frontiers in Medicine</i> , 2020, 7, 599901.	1.2	0
488	Radionuclide imaging of NENs. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 207-215.	0.6	0
489	Molecular imaging with FLT: a case of Cassandra's curse?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2687-2689.	3.3	0
490	PET Diagnosis and Response Monitoring in Oncology. , 2021, , 1049-1076.		0
491	Non-small Cell Lung Carcinoma. , 2008, , 237-247.		0
492	Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases. , 2012, , 661-689.		0
493	A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2-2.	0.8	0
494	Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13524-e13524.	0.8	0
495	Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9540-9540.	0.8	0
496	FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10041-10041.	0.8	0
497	Abstract LB-023: Dynamic real time in vivo CAR T cell tracking: Clinical and preclinical studies using a novel dual PET-MR imaging agent. , 2020, , .		0
498	PERCISTence: Strength or Stubbornness? (perspective on "From RECIST to PERCIST: Evolving) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Journal of Nuclear Medicine</i> , 2020, 61, 199S-226S.	2.8	0
499	On the Inclusion of Specialists as Authors in Systematic Reviews. <i>SpringerBriefs in Ethics</i> , 2020, , 57-66.	0.6	0
500	Combining radionuclide therapy with radiotherapy. , 2021, , .		0
501	PET Imaging of Melanoma. , 2022, , .		0
502	Evaluating the utility of fluorine-18 fluorodeoxyglucose (¹⁸ F-FDG)-positron emission tomography (PET)/ computed tomography (CT) scan in cancer of unknown primary.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3062-3062.	0.8	0